Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets

1.

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014). Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Research, 74, 2913–2921. https://doi.org/10.1158/0008-5472.CAN-14-0155CrossRefPubMed

2.

Qin, C., Yang, G., Yang, J., Ren, B., Wang, H., Chen, G., Zhao, F., You, L., Wang, W., & Zhao, Y. (2020). Metabolism of pancreatic cancer: Paving the way to better anticancer strategies. Molecular Cancer, 19, 50. https://doi.org/10.1186/s12943-020-01169-7CrossRefPubMedPubMedCentral

3.

Wang, S., Zheng, Y., Yang, F., Zhu, L., Zhu, X.-Q., Wang, Z.-F., Wu, X.-L., Zhou, C.-H., Yan, J.-Y., Hu, B.-Y., Kong, B., Fu, D.-L., Bruns, C., Zhao, Y., Qin, L.-X., & Dong, Q.-Z. (2021). The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives. Signal Transduction and Targeted Therapy, 6, 249. https://doi.org/10.1038/s41392-021-00659-4CrossRefPubMedPubMedCentral

4.

Hosein, A. N., Brekken, R. A., & Maitra, A. (2020). Pancreatic cancer stroma: An update on therapeutic targeting strategies. Nature Reviews. Gastroenterology & Hepatology, 17, 487–505. https://doi.org/10.1038/s41575-020-0300-1CrossRef

5.

Alistar, A., Morris, B. B., Desnoyer, R., Klepin, H. D., Hosseinzadeh, K., Clark, C., Cameron, A., Leyendecker, J., D’Agostino, R., Topaloglu, U., Boteju, L. W., Boteju, A. R., Shorr, R., Zachar, Z., Bingham, P. M., Ahmed, T., Crane, S., Shah, R., Migliano, J. J., … Pasche, B. (2017). Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: A single-centre, open-label, dose-escalation, phase 1 trial. The lancet Oncology, 18, 770–778. https://doi.org/10.1016/S1470-2045(17)30314-5CrossRefPubMedPubMedCentral

6.

Jia, Y., & Xie, J. (2015). Promising molecular mechanisms responsible for gemcitabine resistance in cancer. Genes Dis., 2, 299–306. https://doi.org/10.1016/j.gendis.2015.07.003CrossRefPubMedPubMedCentral

7.

Kimmelman, A. C., & White, E. (2017). Autophagy and tumor metabolism. Cell Metabolism, 25, 1037–1043. https://doi.org/10.1016/j.cmet.2017.04.004CrossRefPubMedPubMedCentral

8.

Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012). The pancreas cancer microenvironment. Clinical Cancer Research, 18, 4266–4276. https://doi.org/10.1158/1078-0432.CCR-11-3114CrossRefPubMedPubMedCentral

9.

Halbrook, C. J., & Lyssiotis, C. A. (2017). Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell, 31, 5–19. https://doi.org/10.1016/j.ccell.2016.12.006CrossRefPubMed

10.

Pedersen, S. F., Novak, I., Alves, F., Schwab, A., & Pardo, L. A. (2017). Alternating pH landscapes shape epithelial cancer initiation and progression: Focus on pancreatic cancer. BioEssays, 39, 1600253. https://doi.org/10.1002/bies.201600253CrossRef

11.

Kato, Y., Ozawa, S., Miyamoto, C., Maehata, Y., Suzuki, A., Maeda, T., & Baba, Y. (2013). Acidic extracellular microenvironment and cancer. Cancer Cell International, 13, 89. https://doi.org/10.1186/1475-2867-13-89CrossRefPubMedPubMedCentral

12.

Cruz-Monserrate, Z., Roland, C. L., Deng, D., Arumugam, T., Moshnikova, A., Andreev, O. A., Reshetnyak, Y. K., & Logsdon, C. D. (2015). Targeting pancreatic ductal adenocarcinoma acidic microenvironment. Science and Reports, 4, 4410. https://doi.org/10.1038/srep04410CrossRef

13.

Provenzano, P. P., & Hingorani, S. R. (2013). Hyaluronan, fluid pressure, and stromal resistance in pancreas cancer. British Journal of Cancer, 108, 1–8. https://doi.org/10.1038/bjc.2012.569CrossRefPubMedPubMedCentral

14.

Grasso, C., Jansen, G., & Giovannetti, E. (2017). Drug resistance in pancreatic cancer: Impact of altered energy metabolism. Critical Reviews in Oncology Hematology, 114, 139–152. https://doi.org/10.1016/j.critrevonc.2017.03.026CrossRef

15.

Daemen, A., Peterson, D., Sahu, N., McCord, R., Du, X., Liu, B., Kowanetz, K., Hong, R., Moffat, J., Gao, M., Boudreau, A., Mroue, R., Corson, L., O’Brien, T., Qing, J., Sampath, D., Merchant, M., Yauch, R., Manning, G., … Evangelista, M. (2015). Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proceedings of the National Academy of Sciences, 112, E4410–E4417. https://doi.org/10.1073/pnas.1501605112CrossRef

16.

Viale, A., Pettazzoni, P., Lyssiotis, C. A., Ying, H., Sánchez, N., Marchesini, M., Carugo, A., Green, T., Seth, S., Giuliani, V., Kost-Alimova, M., Muller, F., Colla, S., Nezi, L., Genovese, G., Deem, A. K., Kapoor, A., Yao, W., Brunetto, E., … Draetta, G. F. (2014). Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature, 514, 628–632. https://doi.org/10.1038/nature13611CrossRefPubMedPubMedCentral

17.

Karasinska, J. M., Topham, J. T., Kalloger, S. E., Jang, G. H., Denroche, R. E., Culibrk, L., Williamson, L. M., Wong, H.-L., Lee, M. K. C., O’Kane, G. M., Moore, R. A., Mungall, A. J., Moore, M. J., Warren, C., Metcalfe, A., Notta, F., Knox, J. J., Gallinger, S., Laskin, J., … Schaeffer, D. F. (2020). Altered gene expression along the glycolysis–cholesterol synthesis axis is associated with outcome in pancreatic cancer. Clinical Cancer Research, 26, 135–146. https://doi.org/10.1158/1078-0432.CCR-19-1543CrossRefPubMed

18.

Zecchini, V., & Frezza, C. (1858). Metabolic synthetic lethality in cancer therapy. Biochim. Biophys. Acta BBA - Bioenerg., 2017, 723–731. https://doi.org/10.1016/j.bbabio.2016.12.003CrossRef

19.

Villanueva, M. T. (2018). Metabolic synthetic lethality. Nature Reviews. Drug Discovery, 17, 543–543. https://doi.org/10.1038/nrd.2018.123CrossRefPubMed

20.

Kim, S. S., Xu, S., Cui, J., Poddar, S., Le, T. M., Hayrapetyan, H., Li, L., Wu, N., Moore, A. M., Zhou, L., Yu, A. C., Dann, A. M., Elliott, I. A., Abt, E. R., Kim, W., Dawson, D. W., Radu, C. G., & Donahue, T. R. (2020). Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Theranostics., 10, 829–840. https://doi.org/10.7150/thno.40195CrossRefPubMedPubMedCentral

21.

Cheng, G., Zielonka, J., McAllister, D., Tsai, S., Dwinell, M. B., & Kalyanaraman, B. (2014). Profiling and targeting of cellular bioenergetics: Inhibition of pancreatic cancer cell proliferation. British Journal of Cancer, 111, 85–93. https://doi.org/10.1038/bjc.2014.272CrossRefPubMedPubMedCentral

22.

Zhao, L., Lee, V. H. F., Ng, M. K., Yan, H., & Bijlsma, M. F. (2019). Molecular subtyping of cancer: Current status and moving toward clinical applications. Briefings in Bioinformatics, 20, 572–584. https://doi.org/10.1093/bib/bby026CrossRefPubMed

23.

Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., Bloomfield, C. D., & Lander, E. S. (1999). Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science, 286, 531–537. https://doi.org/10.1126/science.286.5439.531CrossRef

24.

Caldas, C., & Kern, S. E. (1995). K-ras mutation and pancreatic adenocarcinoma. International Journal of Pancreatology, 18, 1–6. https://doi.org/10.1007/BF02825415CrossRefPubMed

25.

Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., Feiler, H. S., Ko, A. H., Olshen, A. B., Danenberg, K. L., Tempero, M. A., Spellman, P. T., Hanahan, D., & Gray, J. W. (2011). Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine, 17, 500–503. https://doi.org/10.1038/nm.2344CrossRefPubMedPubMedCentral

26.

Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., Smyla, J. K., Anderson, J. M., Kim, H. J., Bentrem, D. J., Talamonti, M. S., Iacobuzio-Donahue, C. A., Hollingsworth, M. A., & Yeh, J. J. (2015). Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature Genetics, 47, 1168–1178. https://doi.org/10.1038/ng.3398CrossRefPubMedPubMedCentral

27.

Australian Pancreatic Cancer Genome Initiative, Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., … Grimmond, S. M. (2016). Genomic analyses identify molecular subtypes of pancreatic cancer. Nature., 531, 47–52. https://doi.org/10.1038/nature16965CrossRef

28.

Puleo, F., Nicolle, R., Blum, Y., Cros, J., Marisa, L., Demetter, P., Quertinmont, E., Svrcek, M., Elarouci, N., Iovanna, J., Franchimont, D., Verset, L., Galdon, M. G., Devière, J., de Reyniès, A., Laurent-Puig, P., Van Laethem, J.-L., Bachet, J.-B., & Maréchal, R. (2018). Stratification of pancreatic ductal adenocarcinomas based on tumor and microenvironment features. Gastroenterology, 155, 1999-2013.e3. https://doi.org/10.1053/j.gastro.2018.08.033CrossRefPubMed

29.

Noll, E. M., Eisen, C., Stenzinger, A., Espinet, E., Muckenhuber, A., Klein, C., Vogel, V., Klaus, B., Nadler, W., Rösli, C., Lutz, C., Kulke, M., Engelhardt, J., Zickgraf, F. M., Espinosa, O., Schlesner, M., Jiang, X., Kopp-Schneider, A., Neuhaus, P., … Sprick, M. R. (2016). CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nature Medicine, 22, 278–287. https://doi.org/10.1038/nm.4038CrossRefPubMedPubMedCentral

30.

Zhao, L., Zhao, H., & Yan, H. (2018). Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes. BMC Cancer, 18, 603. https://doi.org/10.1186/s12885-018-4546-8CrossRefPubMedPubMedCentral

31.

DeBerardinis, R. J., & Chandel, N. S. (2016). Fundamentals of cancer metabolism. Science Advances, 2, e1600200. https://doi.org/10.1126/sciadv.1600200CrossRefPubMedPubMedCentral

32.

Chen, X., Li, L., Guan, Y., Yang, J., & Cheng, Y. (2016). Anticancer strategies based on the metabolic profile of tumor cells: Therapeutic targeting of the Warburg effect. Acta Pharmacologica Sinica, 37, 1013–1019. https://doi.org/10.1038/aps.2016.47CrossRefPubMedPubMedCentral

33.

Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., Yan, H., Wang, W., Chen, S., Viale, A., Zheng, H., Paik, J., Lim, C., Guimaraes, A. R., Martin, E. S., … DePinho, R. A. (2012). Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell, 149, 656–670. https://doi.org/10.1016/j.cell.2012.01.058CrossRefPubMedPubMedCentral

34.

Snaebjornsson, M. T., Janaki-Raman, S., & Schulze, A. (2020). Greasing the wheels of the cancer machine: The role of lipid metabolism in cancer. Cell Metabolism, 31, 62–76. https://doi.org/10.1016/j.cmet.2019.11.010CrossRefPubMed

35.

Sunami, Y., Rebelo, A., & Kleeff, J. (2017). Lipid metabolism and lipid droplets in pancreatic cancer and stellate cells. Cancers, 10, 3. https://doi.org/10.3390/cancers10010003CrossRefPubMedCentral

36.

Yabushita, S., Fukamachi, K., Tanaka, H., Fukuda, T., Sumida, K., Deguchi, Y., Mikata, K., Nishioka, K., Kawamura, S., Uwagawa, S., Suzui, M., Alexander, D. B., & Tsuda, H. (2013). Metabolomic and transcriptomic profiling of human K- ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Carcinogenesis, 34, 1251–1259. https://doi.org/10.1093/carcin/bgt053CrossRefPubMed

37.

Tadros, S., Shukla, S. K., King, R. J., Gunda, V., Vernucci, E., Abrego, J., Chaika, N. V., Yu, F., Lazenby, A. J., Berim, L., Grem, J., Sasson, A. R., & Singh, P. K. (2017). De Novo lipid synthesis facilitates gemcitabine resistance through endoplasmic reticulum stress in pancreatic cancer. Cancer Research, 77, 5503–5517. https://doi.org/10.1158/0008-5472.CAN-16-3062CrossRefPubMedPubMedCentral

38.

Hatzivassiliou, G., Zhao, F., Bauer, D. E., Andreadis, C., Shaw, A. N., Dhanak, D., Hingorani, S. R., Tuveson, D. A., & Thompson, C. B. (2005). ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell, 8, 311–321. https://doi.org/10.1016/j.ccr.2005.09.008CrossRefPubMed

39.

Kamphorst, J. J., Cross, J. R., Fan, J., de Stanchina, E., Mathew, R., White, E. P., Thompson, C. B., & Rabinowitz, J. D. (2013). Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proceedings of the National Academy of Sciences, 110, 8882–8887. https://doi.org/10.1073/pnas.1307237110CrossRef

40.

Guillaumond, F., Bidaut, G., Ouaissi, M., Servais, S., Gouirand, V., Olivares, O., Lac, S., Borge, L., Roques, J., Gayet, O., Pinault, M., Guimaraes, C., Nigri, J., Loncle, C., Lavaut, M.-N., Garcia, S., Tailleux, A., Staels, B., Calvo, E., … Vasseur, S. (2015). Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences, 112, 2473–2478. https://doi.org/10.1073/pnas.1421601112CrossRef

41.

Gabitova-Cornell, L., Surumbayeva, A., Peri, S., Franco-Barraza, J., Restifo, D., Weitz, N., Ogier, C., Goldman, A. R., Hartman, T. R., Francescone, R., Tan, Y., Nicolas, E., Shah, N., Handorf, E. A., Cai, K. Q., O’Reilly, A. M., Sloma, I., Chiaverelli, R., Moffitt, R. A., … Astsaturov, I. (2020). Cholesterol pathway inhibition induces TGF-β signaling to promote basal differentiation in pancreatic cancer. Cancer Cell, 38, 567-583.e11. https://doi.org/10.1016/j.ccell.2020.08.015CrossRefPubMedPubMedCentral

42.

Rozeveld, C. N., Johnson, K. M., Zhang, L., & Razidlo, G. L. (2020). KRAS controls pancreatic cancer cell lipid metabolism and invasive potential through the lipase HSL. Cancer Research, 80, 4932–4945. https://doi.org/10.1158/0008-5472.CAN-20-1255CrossRefPubMedPubMedCentral

43.

Kimmelman, A. C. (2015). Metabolic dependencies in RAS -driven cancers. Clinical Cancer Research, 21, 1828–1834. https://doi.org/10.1158/1078-0432.CCR-14-2425CrossRefPubMedPubMedCentral

44.

Kaira, K., Sunose, Y., Arakawa, K., Ogawa, T., Sunaga, N., Shimizu, K., Tominaga, H., Oriuchi, N., Itoh, H., Nagamori, S., Kanai, Y., Segawa, A., Furuya, M., Mori, M., Oyama, T., & Takeyoshi, I. (2012). Prognostic significance of L-type amino-acid transporter 1 expression in surgically resected pancreatic cancer. British Journal of Cancer, 107, 632–638. https://doi.org/10.1038/bjc.2012.310CrossRefPubMedPubMedCentral

45.

Coothankandaswamy, V., Cao, S., Xu, Y., Prasad, P. D., Singh, P. K., Reynolds, C. P., Yang, S., Ogura, J., Ganapathy, V., & Bhutia, Y. D. (2016). Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer: SLC6A14 is a drug target for pancreatic cancer. British Journal of Pharmacology, 173, 3292–3306. https://doi.org/10.1111/bph.13616CrossRefPubMedPubMedCentral

46.

Wise, D. R., & Thompson, C. B. (2010). Glutamine addiction: A new therapeutic target in cancer. Trends in Biochemical Sciences, 35, 427–433. https://doi.org/10.1016/j.tibs.2010.05.003CrossRefPubMedPubMedCentral

47.

Hensley, C. T., Wasti, A. T., & DeBerardinis, R. J. (2013). Glutamine and cancer: Cell biology, physiology, and clinical opportunities. The Journal of Clinical Investigation, 123, 3678–3684. https://doi.org/10.1172/JCI69600CrossRefPubMedPubMedCentral

48.

Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezene, P., Dusetti, N. J., Loncle, C., Calvo, E., Turrini, O., Iovanna, J. L., Tomasini, R., & Vasseur, S. (2013). Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. Proceedings of the National Academy of Sciences, 110, 3919–3924. https://doi.org/10.1073/pnas.1219555110CrossRef

49.

Pupo, E., Avanzato, D., Middonti, E., Bussolino, F., & Lanzetti, L. (2019). KRAS-driven metabolic rewiring reveals novel actionable targets in cancer. Frontiers in Oncology, 9, 848. https://doi.org/10.3389/fonc.2019.00848CrossRefPubMedPubMedCentral

50.

Son, J., Lyssiotis, C. A., Ying, H., Wang, X., Hua, S., Ligorio, M., Perera, R. M., Ferrone, C. R., Mullarky, E., Shyh-Chang, N., Kang, Y., Fleming, J. B., Bardeesy, N., Asara, J. M., Haigis, M. C., DePinho, R. A., Cantley, L. C., & Kimmelman, A. C. (2013). Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature, 496, 101–105. https://doi.org/10.1038/nature12040CrossRefPubMedPubMedCentral

51.

Abrego, J., Gunda, V., Vernucci, E., Shukla, S. K., King, R. J., Dasgupta, A., Goode, G., Murthy, D., Yu, F., & Singh, P. K. (2017). GOT1-mediated anaplerotic glutamine metabolism regulates chronic acidosis stress in pancreatic cancer cells. Cancer Letters, 400, 37–46. https://doi.org/10.1016/j.canlet.2017.04.029CrossRefPubMedPubMedCentral

52.

Pastore, A., Piemonte, F., Locatelli, M., Lo Russo, A., Gaeta, L. M., Tozzi, G., & Federici, G. (2001). Determination of blood total, reduced, and oxidized glutathione in pediatric subjects. Clin. Chem., 47, 1467–1469.CrossRef

53.

Wang, V.M.-Y., Ferreira, R. M. M., Almagro, J., Evan, T., Legrave, N., Zaw Thin, M., Frith, D., Carvalho, J., Barry, D. J., Snijders, A. P., Herbert, E., Nye, E. L., MacRae, J. I., & Behrens, A. (2019). CD9 identifies pancreatic cancer stem cells and modulates glutamine metabolism to fuel tumour growth. Nat. Cell Biol., 21, 1425–1435. https://doi.org/10.1038/s41556-019-0407-1CrossRefPubMedPubMedCentral

54.

Commisso, C., Davidson, S. M., Soydaner-Azeloglu, R. G., Parker, S. J., Kamphorst, J. J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J. A., Thompson, C. B., Rabinowitz, J. D., Metallo, C. M., Vander Heiden, M. G., & Bar-Sagi, D. (2013). Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature., 497, 633–637. https://doi.org/10.1038/nature12138CrossRefPubMedPubMedCentral

55.

Mayers, J. R., Wu, C., Clish, C. B., Kraft, P., Torrence, M. E., Fiske, B. P., Yuan, C., Bao, Y., Townsend, M. K., Tworoger, S. S., Davidson, S. M., Papagiannakopoulos, T., Yang, A., Dayton, T. L., Ogino, S., Stampfer, M. J., Giovannucci, E. L., Qian, Z. R., Rubinson, D. A., … Wolpin, B. M. (2014). Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med., 20, 1193–1198. https://doi.org/10.1038/nm.3686CrossRefPubMedPubMedCentral

56.

Daher, B., Parks, S. K., Durivault, J., Cormerais, Y., Baidarjad, H., Tambutte, E., Pouysségur, J., & Vučetić, M. (2019). Genetic ablation of the cystine transporter xCT in PDAC cells inhibits mTORC1, growth, survival, and tumor formation via nutrient and oxidative stresses. Cancer Research, 79, 3877–3890. https://doi.org/10.1158/0008-5472.CAN-18-3855CrossRefPubMed

57.

Olivares, O., Mayers, J. R., Gouirand, V., Torrence, M. E., Gicquel, T., Borge, L., Lac, S., Roques, J., Lavaut, M.-N., Berthezène, P., Rubis, M., Secq, V., Garcia, S., Moutardier, V., Lombardo, D., Iovanna, J. L., Tomasini, R., Guillaumond, F., Vander Heiden, M. G., & Vasseur, S. (2017). Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. Nat. Commun., 8, 16031. https://doi.org/10.1038/ncomms16031CrossRefPubMedPubMedCentral

58.

Zaytouni, T., Tsai, P.-Y., Hitchcock, D. S., DuBois, C. D., Freinkman, E., Lin, L., Morales-Oyarvide, V., Lenehan, P. J., Wolpin, B. M., Mino-Kenudson, M., Torres, E. M., Stylopoulos, N., Clish, C. B., & Kalaany, N. Y. (2017). Critical role for arginase 2 in obesity-associated pancreatic cancer. Nature Communications, 8, 242. https://doi.org/10.1038/s41467-017-00331-yCrossRefPubMedPubMedCentral

59.

M. New, T. Van Acker, J.S. Long, J. Sakamaki, K.M. Ryan, S.A. Tooze, Molecular pathways controlling autophagy in pancreatic cancer, Front. Oncol. 7 (2017). https://doi.org/10.3389/fonc.2017.00028.

60.

Mowers, E. E., Sharifi, M. N., & Macleod, K. F. (2017). Autophagy in cancer metastasis. Oncogene, 36, 1619–1630. https://doi.org/10.1038/onc.2016.333CrossRefPubMed

61.

Perera, R. M., Stoykova, S., Nicolay, B. N., Ross, K. N., Fitamant, J., Boukhali, M., Lengrand, J., Deshpande, V., Selig, M. K., Ferrone, C. R., Settleman, J., Stephanopoulos, G., Dyson, N. J., Zoncu, R., Ramaswamy, S., Haas, W., & Bardeesy, N. (2015). Transcriptional control of autophagy–lysosome function drives pancreatic cancer metabolism. Nature, 524, 361–365. https://doi.org/10.1038/nature14587CrossRefPubMedPubMedCentral

62.

Yang, M., Liu, E., Tang, L., Lei, Y., Sun, X., Hu, J., Dong, H., Yang, S.-M., Gao, M., & Tang, B. (2018). Emerging roles and regulation of MiT/TFE transcriptional factors. Cell Communication and Signaling: CCS, 16, 31. https://doi.org/10.1186/s12964-018-0242-1CrossRefPubMedPubMedCentral

63.

Kinsey, C. G., Camolotto, S. A., Boespflug, A. M., Guillen, K. P., Foth, M., Truong, A., Schuman, S. S., Shea, J. E., Seipp, M. T., Yap, J. T., Burrell, L. D., Lum, D. H., Whisenant, J. R., Gilcrease, G. W., Cavalieri, C. C., Rehbein, K. M., Cutler, S. L., Affolter, K. E., Welm, A. L., … McMahon, M. (2019). Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nature Medicine, 25, 620–627. https://doi.org/10.1038/s41591-019-0367-9CrossRefPubMedPubMedCentral

64.

Su, H., Yang, F., Fu, R., Li, X., French, R., Mose, E., Pu, X., Trinh, B., Kumar, A., Liu, J., Antonucci, L., Todoric, J., Liu, Y., Hu, Y., Diaz-Meco, M. T., Moscat, J., Metallo, C. M., Lowy, A. M., Sun, B., & Karin, M. (2021). Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosis. Cancer Cell, 39, 678-693.e11. https://doi.org/10.1016/j.ccell.2021.02.016CrossRefPubMed

65.

Karasic, T. B., O’Hara, M. H., Loaiza-Bonilla, A., Reiss, K. A., Teitelbaum, U. R., Borazanci, E., De Jesus-Acosta, A., Redlinger, C., Burrell, J. A., Laheru, D. A., Von Hoff, D. D., Amaravadi, R. K., Drebin, J. A., & O’Dwyer, P. J. (2019). Effect of gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic cancer: A phase 2 randomized clinical trial. JAMA Oncology, 5, 993. https://doi.org/10.1001/jamaoncol.2019.0684CrossRefPubMedPubMedCentral

66.

Amaravadi, R., Kimmelman, A. C., & White, E. (2016). Recent insights into the function of autophagy in cancer. Genes & Development, 30, 1913–1930. https://doi.org/10.1101/gad.287524.116CrossRef

67.

Piffoux, M., Eriau, E., & Cassier, P. A. (2021). Autophagy as a therapeutic target in pancreatic cancer. British Journal of Cancer, 124, 333–344. https://doi.org/10.1038/s41416-020-01039-5CrossRefPubMed

68.

Tian, A.-L., Wu, Q., Liu, P., Zhao, L., Martins, I., Kepp, O., Leduc, M., & Kroemer, G. (2021). Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response. Cell Death & Disease, 12, 6. https://doi.org/10.1038/s41419-020-03324-wCrossRef

69.

Bonam, S. R., Wang, F., & Muller, S. (2019). Lysosomes as a therapeutic target. Nature Reviews. Drug Discovery, 18, 923–948. https://doi.org/10.1038/s41573-019-0036-1CrossRefPubMedPubMedCentral

70.

Levy, J. M. M., Thompson, J. C., Griesinger, A. M., Amani, V., Donson, A. M., Birks, D. K., Morgan, M. J., Mirsky, D. M., Handler, M. H., Foreman, N. K., & Thorburn, A. (2014). Autophagy inhibition improves chemosensitivity in BRAF ^V600E brain tumors. Cancer Discovery, 4, 773–780. https://doi.org/10.1158/2159-8290.CD-14-0049CrossRefPubMedPubMedCentral

71.

Bryant, K. L., Stalnecker, C. A., Zeitouni, D., Klomp, J. E., Peng, S., Tikunov, A. P., Gunda, V., Pierobon, M., Waters, A. M., George, S. D., Tomar, G., Papke, B., Hobbs, G. A., Yan, L., Hayes, T. K., Diehl, J. N., Goode, G. D., Chaika, N. V., Wang, Y., … Der, C. J. (2019). Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nature Medicine, 25, 628–640. https://doi.org/10.1038/s41591-019-0368-8CrossRefPubMedPubMedCentral

72.

Lee, C.-S., Lee, L. C., Yuan, T. L., Chakka, S., Fellmann, C., Lowe, S. W., Caplen, N. J., McCormick, F., & Luo, J. (2019). MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival. Proceedings of the National Academy of Sciences, 116, 4508–4517. https://doi.org/10.1073/pnas.1817494116CrossRef

73.

Morris, J. P., Yashinskie, J. J., Koche, R., Chandwani, R., Tian, S., Chen, C.-C., Baslan, T., Marinkovic, Z. S., Sánchez-Rivera, F. J., Leach, S. D., Carmona-Fontaine, C., Thompson, C. B., Finley, L. W. S., & Lowe, S. W. (2019). α-Ketoglutarate links p53 to cell fate during tumour suppression. Nature, 573, 595–599. https://doi.org/10.1038/s41586-019-1577-5CrossRefPubMedPubMedCentral

74.

Santana-Codina, N., Roeth, A. A., Zhang, Y., Yang, A., Mashadova, O., Asara, J. M., Wang, X., Bronson, R. T., Lyssiotis, C. A., Ying, H., & Kimmelman, A. C. (2018). Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nature Communications, 9, 4945. https://doi.org/10.1038/s41467-018-07472-8CrossRefPubMedPubMedCentral

75.

Schild, T., McReynolds, M. R., Shea, C., Low, V., Schaffer, B. E., Asara, J. M., Piskounova, E., Dephoure, N., Rabinowitz, J. D., Gomes, A. P., & Blenis, J. (2021). NADK is activated by oncogenic signaling to sustain pancreatic ductal adenocarcinoma. Cell Reports, 35, 109238. https://doi.org/10.1016/j.celrep.2021.109238CrossRefPubMed

76.

Ju, H.-Q., Zhuang, Z.-N., Li, H., Tian, T., Lu, Y.-X., Fan, X.-Q., Zhou, H.-J., Mo, H.-Y., Sheng, H., Chiao, P. J., & Xu, R.-H. (2016). Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer. Cancer Letters, 379, 1–11. https://doi.org/10.1016/j.canlet.2016.05.024CrossRefPubMed

77.

Kugel, S., Sebastián, C., Fitamant, J., Ross, K. N., Saha, S. K., Jain, E., Gladden, A., Arora, K. S., Kato, Y., Rivera, M. N., Ramaswamy, S., Sadreyev, R. I., Goren, A., Deshpande, V., Bardeesy, N., & Mostoslavsky, R. (2016). SIRT6 suppresses pancreatic cancer through control of Lin28b. Cell, 165, 1401–1415. https://doi.org/10.1016/j.cell.2016.04.033CrossRefPubMedPubMedCentral

78.

Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015). p53 in survival, death and metabolic health: A lifeguard with a licence to kill. Nature Reviews Molecular Cell Biology, 16, 393–405. https://doi.org/10.1038/nrm4007CrossRefPubMed

79.

Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E. (2004). The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Research, 64, 2627–2633. https://doi.org/10.1158/0008-5472.CAN-03-0846CrossRefPubMed

80.

Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell, 126, 107–120. https://doi.org/10.1016/j.cell.2006.05.036CrossRefPubMed

81.

Rajeshkumar, N. V., Dutta, P., Yabuuchi, S., de Wilde, R. F., Martinez, G. V., Le, A., Kamphorst, J. J., Rabinowitz, J. D., Jain, S. K., Hidalgo, M., Dang, C. V., Gillies, R. J., & Maitra, A. (2015). Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Research, 75, 3355–3364. https://doi.org/10.1158/0008-5472.CAN-15-0108CrossRefPubMedPubMedCentral

82.

Schofield, H. K., Zeller, J., Espinoza, C., Halbrook, C. J., Del Vecchio, A., Magnuson, B., Fabo, T., Daylan, A. E. C., Kovalenko, I., Lee, H.-J., Yan, W., Feng, Y., Karim, S. A., Kremer, D. M., Kumar-Sinha, C., Lyssiotis, C. A., Ljungman, M., Morton, J. P., Galbán, S., … Pasca di Magliano, M. (2018). Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma. JCI Insight., 3, 97422. https://doi.org/10.1172/jci.insight.97422CrossRefPubMed

83.

Nagarajan, A., Dogra, S. K., Sun, L., Gandotra, N., Ho, T., Cai, G., Cline, G., Kumar, P., Cowles, R. A., & Wajapeyee, N. (2017). Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport. Molecular Cell, 67, 685-701.e6. https://doi.org/10.1016/j.molcel.2017.07.014CrossRefPubMedPubMedCentral

84.

Liang, C., Shi, S., Qin, Y., Meng, Q., Hua, J., Hu, Q., Ji, S., Zhang, B., Xu, J., & Yu, X.-J. (2020). Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Gut, 69, 888–900. https://doi.org/10.1136/gutjnl-2018-317163CrossRefPubMed

85.

Ezrova, Z., Nahacka, Z., Stursa, J., Werner, L., Vlcak, E., Kralova Viziova, P., Berridge, M. V., Sedlacek, R., Zobalova, R., Rohlena, J., Boukalova, S., & Neuzil, J. (2021). SMAD4 loss limits the vulnerability of pancreatic cancer cells to complex I inhibition via promotion of mitophagy. Oncogene., 40, 2539–2552. https://doi.org/10.1038/s41388-021-01726-4CrossRefPubMed

86.

Ju, H.-Q., Ying, H., Tian, T., Ling, J., Fu, J., Lu, Y., Wu, M., Yang, L., Achreja, A., Chen, G., Zhuang, Z., Wang, H., Nagrath, D., Yao, J., Hung, M.-C., DePinho, R. A., Huang, P., Xu, R.-H., & Chiao, P. J. (2017). Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Nature Communications, 8, 14437. https://doi.org/10.1038/ncomms14437CrossRefPubMedPubMedCentral

87.

Sullivan, M. R., Danai, L. V., Lewis, C. A., Chan, S. H., Gui, D. Y., Kunchok, T., Dennstedt, E. A., Vander Heiden, M. G., & Muir, A. (2019). Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. ELife., 8, e44235. https://doi.org/10.7554/eLife.44235CrossRefPubMedPubMedCentral

88.

Corbet, C., & Feron, O. (2017). Tumour acidosis: From the passenger to the driver’s seat. Nature Reviews Cancer, 17, 577–593. https://doi.org/10.1038/nrc.2017.77CrossRefPubMed

89.

Boedtkjer, E., & Pedersen, S. F. (2020). The acidic tumor microenvironment as a driver of cancer. Annual Review of Physiology, 82, 103–126. https://doi.org/10.1146/annurev-physiol-021119-034627CrossRefPubMed

90.

Corbet, C., Bastien, E., Santiago de Jesus, J. P., Dierge, E., Martherus, R., Vander Linden, C., Doix, B., Degavre, C., Guilbaud, C., Petit, L., Michiels, C., Dessy, C., Larondelle, Y., & Feron, O. (2020). TGFβ2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat. Commun., 11, 454. https://doi.org/10.1038/s41467-019-14262-3CrossRefPubMedPubMedCentral

91.

LaMonte, G., Tang, X., Chen, J.L.-Y., Wu, J., Ding, C.-K.C., Keenan, M. M., Sangokoya, C., Kung, H.-N., Ilkayeva, O., Boros, L. G., Newgard, C. B., & Chi, J.-T. (2013). Acidosis induces reprogramming of cellular metabolism to mitigate oxidative stress. Cancer Metab., 1, 23. https://doi.org/10.1186/2049-3002-1-23CrossRefPubMedPubMedCentral

92.

Corbet, C., Draoui, N., Polet, F., Pinto, A., Drozak, X., Riant, O., & Feron, O. (2014). The SIRT1/HIF2α axis drives reductive glutamine metabolism under chronic acidosis and alters tumor response to therapy. Cancer Research, 74, 5507–5519. https://doi.org/10.1158/0008-5472.CAN-14-0705CrossRefPubMed

93.

Pedersen, S. F., Flinck, M., & Pardo, L. A. (2021). The interplay between dysregulated ion transport and mitochondrial architecture as a dangerous liaison in cancer. International Journal of Molecular Sciences, 22, 5209. https://doi.org/10.3390/ijms22105209CrossRefPubMedPubMedCentral

94.

Yu, M., Nguyen, N. D., Huang, Y., Lin, D., Fujimoto, T. N., Molkentine, J. M., Deorukhkar, A., Kang, Y., San Lucas, F. A., Fernandes, C. J., Koay, E. J., Gupta, S., Ying, H., Koong, A. C., Herman, J. M., Fleming, J. B., Maitra, A., & Taniguchi, C. M. (2019). Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight., 4, e126915. https://doi.org/10.1172/jci.insight.126915CrossRefPubMedCentral

95.

Koong, A. C., Mehta, V. K., Le, Q. T., Fisher, G. A., Terris, D. J., Brown, J. M., Bastidas, A. J., & Vierra, M. (2000). Pancreatic tumors show high levels of hypoxia. Int. J. Radiat. Oncol., 48, 919–922. https://doi.org/10.1016/S0360-3016(00)00803-8CrossRef

96.

Whatcott, C. J., Diep, C. H., Jiang, P., Watanabe, A., LoBello, J., Sima, C., Hostetter, G., Shepard, H. M., Von Hoff, D. D., & Han, H. (2015). Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clinical Cancer Research, 21, 3561–3568. https://doi.org/10.1158/1078-0432.CCR-14-1051CrossRefPubMedPubMedCentral

97.

Rice, A. J., Cortes, E., Lachowski, D., Cheung, B. C. H., Karim, S. A., Morton, J. P., & del Río Hernández, A. (2017). Matrix stiffness induces epithelial–mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. Oncogenesis., 6, e352–e352. https://doi.org/10.1038/oncsis.2017.54CrossRefPubMedPubMedCentral

98.

Nguyen, A. V., Nyberg, K. D., Scott, M. B., Welsh, A. M., Nguyen, A. H., Wu, N., Hohlbauch, S. V., Geisse, N. A., Gibb, E. A., Robertson, A. G., Donahue, T. R., & Rowat, A. C. (2016). Stiffness of pancreatic cancer cells is associated with increased invasive potential. Integrative Biology, 8, 1232–1245. https://doi.org/10.1039/C6IB00135ACrossRefPubMedPubMedCentral

99.

Rath, N., & Olson, M. F. (2016). Regulation of pancreatic cancer aggressiveness by stromal stiffening. Nature Medicine, 22, 462–463. https://doi.org/10.1038/nm.4099CrossRefPubMed

100.

Liberti, M. V., & Birsoy, K. (2020). A link between metabolic energetics and pancreatic cancer mechanosensing. Nature Metabolism, 2, 5–6. https://doi.org/10.1038/s42255-019-0165-1CrossRefPubMed

101.

Ge, H., Tian, M., Pei, Q., Tan, F., & Pei, H. (2021). Extracellular matrix stiffness: New areas affecting cell metabolism. Frontiers in Oncology, 11, 631991. https://doi.org/10.3389/fonc.2021.631991CrossRefPubMedPubMedCentral

102.

Gore, J., & Korc, M. (2014). Pancreatic cancer stroma: Friend or foe? Cancer Cell, 25, 711–712. https://doi.org/10.1016/j.ccr.2014.05.026CrossRefPubMedPubMedCentral

103.

Maitra, A., & Hruban, R. H. (2008). Pancreatic cancer. Annual Review of Pathology: Mechanisms of Disease, 3, 157–188. https://doi.org/10.1146/annurev.pathmechdis.3.121806.154305CrossRef

104.

Erkan, M., Adler, G., Apte, M. V., Bachem, M. G., Buchholz, M., Detlefsen, S., Esposito, I., Friess, H., Gress, T. M., Habisch, H.-J., Hwang, R. F., Jaster, R., Kleeff, J., Klöppel, G., Kordes, C., Logsdon, C. D., Masamune, A., Michalski, C. W., Oh, J., … Wilson, J. (2012). StellaTUM: Current consensus and discussion on pancreatic stellate cell research. Gut, 61, 172–178. https://doi.org/10.1136/gutjnl-2011-301220CrossRefPubMed

105.

Xue, R., Jia, K., Wang, J., Yang, L., Wang, Y., Gao, L., & Hao, J. (2018). A rising star in pancreatic diseases: Pancreatic stellate cells. Frontiers in Physiology, 9, 754. https://doi.org/10.3389/fphys.2018.00754CrossRefPubMedPubMedCentral

106.

Auciello, F. R., Bulusu, V., Oon, C., Tait-Mulder, J., Berry, M., Bhattacharyya, S., Tumanov, S., Allen-Petersen, B. L., Link, J., Kendsersky, N. D., Vringer, E., Schug, M., Novo, D., Hwang, R. F., Evans, R. M., Nixon, C., Dorrell, C., Morton, J. P., Norman, J. C., … Sherman, M. H. (2019). A stromal lysolipid–autotaxin signaling axis promotes pancreatic tumor progression. Cancer Discovery, 9, 617–627. https://doi.org/10.1158/2159-8290.CD-18-1212CrossRefPubMedPubMedCentral

107.

Apte, M. V., Yang, L., Phillips, P. A., Xu, Z., Kaplan, W., Cowley, M., Pirola, R. C., & Wilson, J. S. (2013). Extracellular matrix composition significantly influences pancreatic stellate cell gene expression pattern: Role of transgelin in PSC function, Am. J. Physiol.-Gastrointest. Liver Physiol., 305, G408–G417. https://doi.org/10.1152/ajpgi.00016.2013CrossRef

108.

Sousa, C. M., Biancur, D. E., Wang, X., Halbrook, C. J., Sherman, M. H., Zhang, L., Kremer, D., Hwang, R. F., Witkiewicz, A. K., Ying, H., Asara, J. M., Evans, R. M., Cantley, L. C., Lyssiotis, C. A., & Kimmelman, A. C. (2016). Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature, 536, 479–483. https://doi.org/10.1038/nature19084CrossRefPubMedPubMedCentral

109.

Helms, E., Onate, M. K., & Sherman, M. H. (2020). Fibroblast heterogeneity in the pancreatic tumor microenvironment. Cancer Discovery, 10, 648–656. https://doi.org/10.1158/2159-8290.CD-19-1353CrossRefPubMedPubMedCentral

110.

Yang, X., Li, Y., Zou, L., & Zhu, Z. (2019). Role of exosomes in crosstalk between cancer-associated fibroblasts and cancer cells. Frontiers in Oncology, 9, 356. https://doi.org/10.3389/fonc.2019.00356CrossRefPubMedPubMedCentral

111.

Chen, S., Chen, X., Shan, T., Ma, J., Lin, W., Li, W., & Kang, Y. (2018). MiR-21-mediated metabolic alteration of cancer-associated fibroblasts and its effect on pancreatic cancer cell behavior. International Journal of Biological Sciences, 14, 100–110. https://doi.org/10.7150/ijbs.22555CrossRefPubMedPubMedCentral

112.

Collins, M. A., Bednar, F., Zhang, Y., Brisset, J.-C., Galbán, S., Galbán, C. J., Rakshit, S., Flannagan, K. S., Adsay, N. V., & Pasca di Magliano, M. (2012). Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. The Journal of Clinical Investigation, 122, 639–653. https://doi.org/10.1172/JCI59227CrossRefPubMedPubMedCentral

113.

Ricard, N., Bailly, S., Guignabert, C., & Simons, M. (2021). The quiescent endothelium: Signalling pathways regulating organ-specific endothelial normalcy. Nature Reviews. Cardiology, 18, 565–580. https://doi.org/10.1038/s41569-021-00517-4CrossRefPubMed

114.

De Bock, K., Georgiadou, M., Schoors, S., Kuchnio, A., Wong, B. W., Cantelmo, A. R., Quaegebeur, A., Ghesquière, B., Cauwenberghs, S., Eelen, G., Phng, L.-K., Betz, I., Tembuyser, B., Brepoels, K., Welti, J., Geudens, I., Segura, I., Cruys, B., Bifari, F., … Carmeliet, P. (2013). Role of PFKFB3-driven glycolysis in vessel sprouting. Cell, 154, 651–663. https://doi.org/10.1016/j.cell.2013.06.037CrossRefPubMed

115.

Ghesquière, B., Wong, B. W., Kuchnio, A., & Carmeliet, P. (2014). Metabolism of stromal and immune cells in health and disease. Nature, 511, 167–176. https://doi.org/10.1038/nature13312CrossRefPubMed

116.

De Saedeleer, C. J., Copetti, T., Porporato, P. E., Verrax, J., Feron, O., & Sonveaux, P. (2012). Lactate Activates HIF-1 in Oxidative but Not in Warburg-Phenotype Human Tumor Cells. PLoS ONE, 7, e46571. https://doi.org/10.1371/journal.pone.0046571CrossRefPubMedPubMedCentral

117.

Végran, F., Boidot, R., Michiels, C., Sonveaux, P., & Feron, O. (2011). Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Research, 71, 2550–2560. https://doi.org/10.1158/0008-5472.CAN-10-2828CrossRefPubMed

118.

Bear, A. S., Vonderheide, R. H., & O’Hara, M. H. (2020). Challenges and opportunities for pancreatic cancer immunotherapy. Cancer Cell, 38, 788–802. https://doi.org/10.1016/j.ccell.2020.08.004CrossRefPubMedPubMedCentral

119.

E. Costello, The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion, Front. Physiol. 3 (2012). https://doi.org/10.3389/fphys.2012.00270.

120.

Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., & Vonderheide, R. H. (2007). Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Research, 67, 9518–9527. https://doi.org/10.1158/0008-5472.CAN-07-0175CrossRefPubMed

121.

Palucka, A. K., & Coussens, L. M. (2016). The Basis of Oncoimmunology. Cell, 164, 1233–1247. https://doi.org/10.1016/j.cell.2016.01.049CrossRefPubMedPubMedCentral

122.

Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., & Hanahan, D. (2000). Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2, 737–744. https://doi.org/10.1038/35036374CrossRefPubMedPubMedCentral

123.

Pylayeva-Gupta, Y., Das, S., Handler, J. S., Hajdu, C. H., Coffre, M., Koralov, S. B., & Bar-Sagi, D. (2016). IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discovery, 6, 247–255. https://doi.org/10.1158/2159-8290.CD-15-0843CrossRefPubMed

124.

Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., Hoshino, A., Mark, M. T., Molina, H., Xiang, J., Zhang, T., Theilen, T.-M., García-Santos, G., Williams, C., Ararso, Y., Huang, Y., Rodrigues, G., Shen, T.-L., … Lyden, D. (2015). Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nature Cell Biology, 17, 816–826. https://doi.org/10.1038/ncb3169CrossRefPubMedPubMedCentral

125.

Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., Cline, G. W., Phillips, A. J., & Medzhitov, R. (2014). Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature, 513, 559–563. https://doi.org/10.1038/nature13490CrossRefPubMedPubMedCentral

126.

Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., Renner, K., Timischl, B., Mackensen, A., Kunz-Schughart, L., Andreesen, R., Krause, S. W., & Kreutz, M. (2007). Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 109, 3812–3819. https://doi.org/10.1182/blood-2006-07-035972CrossRefPubMed

127.

Husain, Z., Huang, Y., Seth, P., & Sukhatme, V. P. (2013). Tumor-derived lactate modifies antitumor immune response: Effect on myeloid-derived suppressor cells and NK cells. The Journal of Immunology, 191, 1486–1495. https://doi.org/10.4049/jimmunol.1202702CrossRefPubMed

128.

Hossain, F., Al-Khami, A. A., Wyczechowska, D., Hernandez, C., Zheng, L., Reiss, K., Valle, L. D., Trillo-Tinoco, J., Maj, T., Zou, W., Rodriguez, P. C., & Ochoa, A. C. (2015). Inhibition of fatty acid oxidation modulates immunosuppressive functions of myeloid-derived suppressor cells and enhances cancer therapies, Cancer. Immunologic Research, 3, 1236–1247. https://doi.org/10.1158/2326-6066.CIR-15-0036CrossRef

129.

Jian, S.-L., Chen, W.-W., Su, Y.-C., Su, Y.-W., Chuang, T.-H., Hsu, S.-C., & Huang, L.-R. (2017). Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. Cell Death & Disease, 8, e2779–e2779. https://doi.org/10.1038/cddis.2017.192CrossRef

130.

Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012). Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Seminars in Cancer Biology, 22, 275–281. https://doi.org/10.1016/j.semcancer.2012.01.011CrossRefPubMedPubMedCentral

131.

Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004). Antigen-specific inhibition of CD8 ⁺ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. The Journal of Immunology, 172, 989–999. https://doi.org/10.4049/jimmunol.172.2.989CrossRefPubMed

132.

Strouch, M. J., Cheon, E. C., Salabat, M. R., Krantz, S. B., Gounaris, E., Melstrom, L. G., Dangi-Garimella, S., Wang, E., Munshi, H. G., Khazaie, K., & Bentrem, D. J. (2010). Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clinical Cancer Research, 16, 2257–2265. https://doi.org/10.1158/1078-0432.CCR-09-1230CrossRefPubMedPubMedCentral

133.

Angst, E., Reber, H. A., Hines, O. J., & Eibl, G. (2008). Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery., 144, 57–65. https://doi.org/10.1016/j.surg.2008.03.024CrossRefPubMed

134.

Chang, C.-H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J. W., Tonc, E., Schreiber, R. D., Pearce, E. J., & Pearce, E. L. (2015). Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, 162, 1229–1241. https://doi.org/10.1016/j.cell.2015.08.016CrossRefPubMedPubMedCentral

135.

Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010). Hypoxia-Inducible Factors and the Response to Hypoxic Stress. Molecular Cell, 40, 294–309. https://doi.org/10.1016/j.molcel.2010.09.022CrossRefPubMedPubMedCentral

136.

Hui, S., Ghergurovich, J. M., Morscher, R. J., Jang, C., Teng, X., Lu, W., Esparza, L. A., Reya, T., Le Zhan, J., Yanxiang Guo, E., & White, J.D. Rabinowitz. (2017). Glucose feeds the TCA cycle via circulating lactate. Nature., 551, 115–118. https://doi.org/10.1038/nature24057CrossRefPubMedPubMedCentral

137.

Dovmark, T. H., Saccomano, M., Hulikova, A., Alves, F., & Swietach, P. (2017). Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells. Oncogene, 36, 4538–4550. https://doi.org/10.1038/onc.2017.71CrossRefPubMedPubMedCentral

138.

Dovmark, T. H., Hulikova, A., Niederer, S. A., Vaughan-Jones, R. D., & Swietach, P. (2018). Normoxic cells remotely regulate the acid-base balance of cells at the hypoxic core of connexin-coupled tumor growths. The FASEB Journal, 32, 83–96. https://doi.org/10.1096/fj.201700480rCrossRefPubMed

139.

Lundø, K., Trauelsen, M., Pedersen, S. F., & Schwartz, T. W. (2020). Why Warburg works: Lactate controls immune evasion through GPR81. Cell Metabolism, 31, 666–668. https://doi.org/10.1016/j.cmet.2020.03.001CrossRefPubMed

140.

Roland, C. L., Arumugam, T., Deng, D., Liu, S. H., Philip, B., Gomez, S., Burns, W. R., Ramachandran, V., Wang, H., Cruz-Monserrate, Z., & Logsdon, C. D. (2014). Cell surface lactate receptor GPR81 is crucial for cancer cell survival. Cancer Research, 74, 5301–5310. https://doi.org/10.1158/0008-5472.CAN-14-0319CrossRefPubMedPubMedCentral

141.

Certo, M., Tsai, C.-H., Pucino, V., Ho, P.-C., & Mauro, C. (2021). Lactate modulation of immune responses in inflammatory versus tumour microenvironments. Nature Reviews Immunology, 21, 151–161. https://doi.org/10.1038/s41577-020-0406-2CrossRefPubMed

142.

Hutcheson, J., Balaji, U., Porembka, M. R., Wachsmann, M. B., McCue, P. A., Knudsen, E. S., & Witkiewicz, A. K. (2016). Immunologic and metabolic features of pancreatic ductal adenocarcinoma define prognostic subtypes of disease. Clinical Cancer Research, 22, 3606–3617. https://doi.org/10.1158/1078-0432.CCR-15-1883CrossRefPubMedPubMedCentral

143.

Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., & Jørgensen, C. (2016). Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation. Cell, 165, 910–920. https://doi.org/10.1016/j.cell.2016.03.029CrossRefPubMedPubMedCentral

144.

Zeng, P. (2019). Lan, Grützmann, Pilarsky, Yang, Chemoresistance in pancreatic cancer. International Journal of Molecular Sciences, 20, 4504. https://doi.org/10.3390/ijms20184504CrossRefPubMedCentral

145.

Schellenberg, D., Quon, A., Minn, A. Y., Graves, E. E., Kunz, P., Ford, J. M., Fisher, G. A., Goodman, K. A., Koong, A. C., & Chang, D. T. (2010). 18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int. J. Radiat. Oncol., 77, 1420–1425. https://doi.org/10.1016/j.ijrobp.2009.06.049CrossRef

146.

Chaika, N. V., Gebregiworgis, T., Lewallen, M. E., Purohit, V., Radhakrishnan, P., Liu, X., Zhang, B., Mehla, K., Brown, R. B., Caffrey, T., Yu, F., Johnson, K. R., Powers, R., Hollingsworth, M. A., & Singh, P. K. (2012). MUC1 mucin stabilizes and activates hypoxia-inducible factor 1 alpha to regulate metabolism in pancreatic cancer. Proceedings of the National Academy of Sciences, 109, 13787–13792. https://doi.org/10.1073/pnas.1203339109CrossRef

147.

Gunda, V., Souchek, J., Abrego, J., Shukla, S. K., Goode, G. D., Vernucci, E., Dasgupta, A., Chaika, N. V., King, R. J., Li, S., Wang, S., Yu, F., Bessho, T., Lin, C., & Singh, P. K. (2017). MUC1-mediated metabolic alterations regulate response to radiotherapy in pancreatic cancer. Clinical Cancer Research, 23, 5881–5891. https://doi.org/10.1158/1078-0432.CCR-17-1151CrossRefPubMedPubMedCentral

148.

Cortez, N. E., & Mackenzie, G. G. (2021). Ketogenic diets in pancreatic cancer and associated cachexia: Cellular mechanisms and clinical perspectives. Nutrients, 13, 3202. https://doi.org/10.3390/nu13093202CrossRefPubMedPubMedCentral

149.

Weber, D. D., Aminzadeh-Gohari, S., Tulipan, J., Catalano, L., Feichtinger, R. G., & Kofler, B. (2020). Ketogenic diet in the treatment of cancer – Where do we stand? Mol. Metab., 33, 102–121. https://doi.org/10.1016/j.molmet.2019.06.026CrossRefPubMed

150.

Lien, E. C., Westermark, A. M., Zhang, Y., Yuan, C., Li, Z., Lau, A. N., Sapp, K. M., Wolpin, B. M., & Vander Heiden, M. G. (2021). Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature., 599, 302–307. https://doi.org/10.1038/s41586-021-04049-2CrossRefPubMed

151.

Salani, B., Marini, C., Rio, A. D., Ravera, S., Massollo, M., Orengo, A. M., Amaro, A., Passalacqua, M., Maffioli, S., Pfeffer, U., Cordera, R., Maggi, D., & Sambuceti, G. (2013). Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. Science and Reports, 3, 2070. https://doi.org/10.1038/srep02070CrossRef

152.

Yasmeen, A., Beauchamp, M.-C., Piura, E., Segal, E., Pollak, M., & Gotlieb, W. H. (2011). Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecologic Oncology, 121, 492–498. https://doi.org/10.1016/j.ygyno.2011.02.021CrossRefPubMed

153.

Nair, V., Sreevalsan, S., Basha, R., Abdelrahim, M., Abudayyeh, A., Rodrigues Hoffman, A., & Safe, S. (2014). Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: Role of specificity protein (Sp) transcription factors. J. Biol. Chem., 289, 27692–27701. https://doi.org/10.1074/jbc.M114.592576CrossRefPubMedPubMedCentral

154.

Hart, T., Dider, S., Han, W., Xu, H., Zhao, Z., & Xie, L. (2016). Toward repurposing metformin as a precision anti-cancer therapy using structural systems pharmacology. Science and Reports, 6, 20441. https://doi.org/10.1038/srep20441CrossRef

155.

Waise, T. M. Z., Rasti, M., Duca, F. A., Zhang, S.-Y., Bauer, P. V., Rhodes, C. J., & Lam, T. K. T. (2019). Inhibition of upper small intestinal mTOR lowers plasma glucose levels by inhibiting glucose production. Nature Communications, 10, 714. https://doi.org/10.1038/s41467-019-08582-7CrossRefPubMedPubMedCentral

156.

Fares, M., Abedi-Valugerdi, M., Hassan, M., & Potácová, Z. (2015). DNA damage, lysosomal degradation and Bcl-xL deamidation in doxycycline- and minocycline-induced cell death in the K562 leukemic cell line. Biochemical and Biophysical Research Communications, 463, 268–274. https://doi.org/10.1016/j.bbrc.2015.05.043CrossRefPubMed

157.

Doudican, N. A., Pennell, R., Byron, S., Pollock, P., Liebes, L., Osman, I., & Orlow, S. (2010). Mebendazole in the treatment of melanoma: The role of Bcl-2 in predicting response and enhancing efficacy. Journal of Clinical Oncology, 28, e19021–e19021. https://doi.org/10.1200/jco.2010.28.15_suppl.e19021CrossRef

158.

Hirao, T., Yamaguchi, M., Kikuya, M., Chibana, H., Ito, K., & Aoki, S. (2018). Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells. Cancer Science, 109, 121–131. https://doi.org/10.1111/cas.13442CrossRefPubMed

159.

Qi, X.-F., Zheng, L., Lee, K.-J., Kim, D.-H., Kim, C.-S., Cai, D.-Q., Wu, Z., Qin, J.-W., Yu, Y.-H., & Kim, S.-K. (2013). HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death & Disease, 4, e518–e518. https://doi.org/10.1038/cddis.2013.44CrossRef

160.

Kimura, T., Takabatake, Y., Takahashi, A., & Isaka, Y. (2013). Chloroquine in cancer therapy: A double-edged sword of autophagy. Cancer Research, 73, 3–7. https://doi.org/10.1158/0008-5472.CAN-12-2464CrossRefPubMed

161.

Kim, E. L., Wüstenberg, R., Rübsam, A., Schmitz-Salue, C., Warnecke, G., Bücker, E.-M., Pettkus, N., Speidel, D., Rohde, V., Schulz-Schaeffer, W., Deppert, W., & Giese, A. (2010). Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro-Oncol., 12, 389–400. https://doi.org/10.1093/neuonc/nop046CrossRefPubMedPubMedCentral

162.

García-Cañaveras, J. C., & Lahoz, A. (2021). Tumor microenvironment-derived metabolites: A guide to find new metabolic therapeutic targets and biomarkers. Cancers, 13, 3230. https://doi.org/10.3390/cancers13133230CrossRefPubMedPubMedCentral

163.

Hezel, A. F. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Development, 20, 1218–1249. https://doi.org/10.1101/gad.1415606CrossRef

164.

Shi, M., Cui, J., Du, J., Wei, D., Jia, Z., Zhang, J., Zhu, Z., Gao, Y., & Xie, K. (2014). A novel KLF4/LDHA signaling pathway regulates aerobic glycolysis in and progression of pancreatic cancer. Clinical Cancer Research, 20, 4370–4380. https://doi.org/10.1158/1078-0432.CCR-14-0186CrossRefPubMedPubMedCentral

165.

Rozenblum, E., Schutte, M., Goggins, M., Hahn, S. A., Panzer, S., Zahurak, M., Goodman, S. N., Sohn, T. A., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1997). Tumor-suppressive pathways in pancreatic carcinoma. Cancer Research, 57, 1731–1734.PubMed

166.

Buscail, L., Bournet, B., & Cordelier, P. (2020). Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nature Reviews. Gastroenterology & Hepatology, 17, 153–168. https://doi.org/10.1038/s41575-019-0245-4CrossRef

167.

Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., & Wooster, R. (2004). The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. British Journal of Cancer, 91, 355–358. https://doi.org/10.1038/sj.bjc.6601894CrossRefPubMedPubMedCentral

168.

Lowman, X. H., Hanse, E. A., Yang, Y., Ishak Gabra, M. B., Tran, T. Q., Li, H., & Kong, M. (2019). p53 promotes cancer cell adaptation to glutamine deprivation by upregulating Slc7a3 to increase arginine uptake. Cell Rep., 26, 3051-3060.e4. https://doi.org/10.1016/j.celrep.2019.02.037CrossRefPubMedPubMedCentral

169.

Matoba, S. (2006). p53 regulates mitochondrial respiration. Science, 312, 1650–1653. https://doi.org/10.1126/science.1126863CrossRefPubMed

170.

Contractor, T., & Harris, C. R. (2012). p53 negatively regulates transcription of the pyruvate dehydrogenase kinase Pdk2. Cancer Research, 72, 560–567. https://doi.org/10.1158/0008-5472.CAN-11-1215CrossRefPubMed

171.

Jiang, P., Du, W., Wang, X., Mancuso, A., Gao, X., Wu, M., & Yang, X. (2011). p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nature Cell Biology, 13, 310–316. https://doi.org/10.1038/ncb2172CrossRefPubMedPubMedCentral

172.

Oshima, M., Okano, K., Muraki, S., Haba, R., Maeba, T., Suzuki, Y., & Yachida, S. (2013). Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer. Annals of Surgery, 258, 336–346. https://doi.org/10.1097/SLA.0b013e3182827a65CrossRefPubMed

173.

Schutte, M., Hruban, R. H., Geradts, J., Maynard, R., Hilgers, W., Rabindran, S. K., Moskaluk, C. A., Hahn, S. A., Schwarte-Waldhoff, I., Schmiegel, W., Baylin, S. B., Kern, S. E., & Herman, J. G. (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Research, 57, 3126–3130.PubMed

174.

Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., Parsons, D. W., Lin, J.C.-H., Leary, R. J., Eshleman, J. R., Goggins, M., Jaffee, E. M., Iacobuzio-Donahue, C. A., Maitra, A., Cameron, J. L., Olino, K., Schulick, R., Winter, J., Herman, J. M., … Hruban, R. H. (2009). SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clinical Cancer Research, 15, 4674–4679. https://doi.org/10.1158/1078-0432.CCR-09-0227CrossRefPubMedPubMedCentral

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets

Abstract

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Tumor metabolism: metabolic alterations and heterogeneity in cancer progression

Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX

The role of metabolic ecosystem in cancer progression — metabolic plasticity and mTOR hyperactivity in tumor tissues

What do cellular responses to acidity tell us about cancer?

Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations

Extracellular citrate and metabolic adaptations of cancer cells

Keynote webinar | Spotlight on antibody–drug conjugates in cancer